Good, But Could Go Further: Industry On EMA's planned Priority Medicines Scheme
This article was originally published in Scrip
Executive Summary
If all goes to plan, the European Medicines Agency will shortly be offering companies yet another tool for expediting the development of innovative drugs for major public health needs: the PRIME (priority medicines) scheme, which is expected to be put out for consultation around the end of October.